Novo Nordisk Announces New Data on Psychosocial Impact of People Living with Hemophilia B

Note: The below is an edited version of a press release by Novo Nordisk. The original release can be read in it’s entirety here. 

Novo Nordisk today announced the first results from the Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B-HERO-S) study, which found that many adults and children living with even mild or moderate hemophilia B in the United States experience a negative impact on their career, education and recreational activities as a result of the disorder. These findings were presented today in Orlando, Florida at the largest international meeting for the global bleeding disorders community, the World Federation of Hemophilia (WFH) 2016 World Congress.